SO
ACRS icon

STRS Ohio’s Aclaris Therapeutics ACRS Stock Holding History

STRS Ohio’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60K Buy
+16,000
New +$54K ﹤0.01% 1901
2024
Q2 		– Sell
-264,700
Closed -$328K – 1950
2024
Q1 		$328K Buy
264,700
+71,700
+37% +$85.5K ﹤0.01% 1411
2023
Q4 		$202K Buy
193,000
+138,900
+257% +$424K ﹤0.01% 1555
2023
Q3 		$370K Hold
54,100
– – ﹤0.01% 1385
2023
Q2 		$561K Buy
54,100
+4,200
+8% +$38K ﹤0.01% 1213
2023
Q1 		$403K Buy
49,900
+13,500
+37% +$171K ﹤0.01% 1409
2022
Q4 		$573K Buy
36,400
+16,500
+83% +$265K ﹤0.01% 1250
2022
Q3 		$313K Buy
19,900
+2,000
+11% +$31.5K ﹤0.01% 1481
2022
Q2 		$249K Buy
+17,900
New +$251K ﹤0.01% 1541
2021
Q4 		– Sell
-6,700
Closed -$120K – 2179
2021
Q3 		$120K Sell
6,700
-10,200
-60% -$164K ﹤0.01% 1908
2021
Q2 		$296K Buy
+16,900
New +$384K ﹤0.01% 1722
2017
Q2 		– Sell
-21,100
Closed -$629K – 1926
2017
Q1 		$629K Buy
+21,100
New +$608K ﹤0.01% 1220
2016
Q4 		– Sell
-8,100
Closed -$207K – 1910
2016
Q3 		$207K Buy
8,100
+5,100
+170% +$108K ﹤0.01% 1544
2016
Q2 		$55K Buy
3,000
+1,100
+58% +$21.8K ﹤0.01% 1754
2016
Q1 		$36K Hold
1,900
– – ﹤0.01% 1792
2015
Q4 		$51K Buy
+1,900
New +$37K ﹤0.01% 1791

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

STRS Ohio's ACRS Position: Q1 2026 in Review

STRS Ohio opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 16,000 shares worth $60K. The stake represents ﹤0.01% of the portfolio and ranks #1901 among its holdings. This is a return to the name: STRS Ohio previously reported a position in ACRS as recently as Q1 2024.

STRS Ohio first reported a position in ACRS in Q4 2015 and has held it in 16 quarters since. The position peaked at $629K in Q1 2017. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • STRS Ohio held 16,000 shares of Aclaris Therapeutics worth $60K as of Q1 2026.
  • Aclaris Therapeutics was a new STRS Ohio position in Q1 2026.
  • Aclaris Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q1 2026, its #1901 holding.
  • STRS Ohio first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 16 quarters since.
  • STRS Ohio's Aclaris Therapeutics position peaked at $629K in Q1 2017.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on STRS Ohio's 13F filing for Q1 2026, filed 24 Apr 2026.